Zynerba ends 4Q with $67.8M cash runway to advance Zygel CBD Gel for Fragile X Syndrome

Описание к видео Zynerba ends 4Q with $67.8M cash runway to advance Zygel CBD Gel for Fragile X Syndrome

Zynerba Pharmaceuticals Inc CEO Armando Anido updated Proactive on results for the fourth quarter and full-year, including $67.8M cash on hand, giving the company scope to run pivotal trials of its flagship product Zygel.

Zygel reently received orphan drug designation from the European Commission. Management believes the company's $67.8 million war chest will be “sufficient” to fund operations and capital requirements into the second half of 2023.

Комментарии

Информация по комментариям в разработке

Похожие видео